Considering the nearly 25% frequency of KRas mutations in non-small-cell lung cancer (NSCLC), we set out to use diverse KRas-expressing NSCLC cell models to identify this novel antitumor strategy. Here, KRAS is linked to non-small cell lung carcinoma.